Interleukin-5 (IL-5) Therapy Prevents Allograft Rejection by Promoting CD4+CD25+ Ts2 Regulatory Cells That Are Antigen-Specific and Express IL-5 Receptor

por Bruce M. Hall, Bruce M. Hall, Rachael M. Hall, Rachael M. Hall, Giang T. Tran, Giang T. Tran, Catherine M. Robinson, Catherine M. Robinson, Paul L. Wilcox, Paul L. Wilcox, Prateek K. Rakesh, Prateek K. Rakesh, Chuanmin Wang, Alexandra F. Sharland, Nirupama D. Verma, Nirupama D. Verma, Suzanne J. Hodgkinson, Suzanne J. Hodgkinson
Publicado 2021